Provided By GlobeNewswire
Last update: Nov 26, 2025
HOUSTON, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that it filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-25 reverse stock split of its common stock. The reverse stock split will take effect at 12:01 am (Eastern Time) on December 1, 2025, and the Company’s common stock will open for trading on The Nasdaq Capital Market on December 1, 2025 on a post-split basis, under the existing ticker symbol “MBRX” but with a new CUSIP number 60855D 408.
Read more at globenewswire.com0.28
-0.08 (-22.03%)
Find more stocks in the Stock Screener


